(S)-N-((S)-1-amino-3-hydroxy-1-oxopropan-2-yl)-1-((S)-1-((S)-2-amino-3-hydroxypropanoyl)pyrrolidine-2-carbonyl)pyrrolidine-2-carboxamide | 1421866-44-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-N-((S)-1-amino-3-hydroxy-1-oxopropan-2-yl)-1-((S)-1-((S)-2-amino-3-hydroxypropanoyl)pyrrolidine-2-carbonyl)pyrrolidine-2-carboxamide
• 英文别名: (S)-N-((S)-1-amino-3-hydroxy-1-oxopropan-2-yl)-1-((S)-1-((S)-2-amino-3-hydroxy-propanoyl)-pyrrolidine-2-carbonyl)-pyrrolidine-2-carboxamide；(2S)-N-[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]-1-[(2S)-1-[(2S)-2-amino-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide
• CAS: 1421866-44-5
• 化学式: C₁₆H₂₇N₅O₆
• 分子量: 385.42
• InChiKey: ZRDKPMDWWRFAAM-BJDJZHNGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.6
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  179
• 氢给体数：
  5
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  benzyl (S)-1-((S)-2-((S)-2-((S)-1-amino-3-hydroxy-1-oxopropan-2-ylcarbamoyl)pyrrolidine-1-carbonyl)pyrrolidin-1-yl)-3-hydroxy-1-oxopropan-2-ylcarbamate 在 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以68%的产率得到(S)-N-((S)-1-amino-3-hydroxy-1-oxopropan-2-yl)-1-((S)-1-((S)-2-amino-3-hydroxypropanoyl)pyrrolidine-2-carbonyl)pyrrolidine-2-carboxamide
  参考文献：
  名称：

  用于治疗精神分裂症、双相障碍、认知损害和重度抑郁障碍的非典型抗精神病药和NMDA调节剂的药物组合

  摘要：

  本公开的特征在于NMDA调节剂和非典型抗精神病药的组合。本公开提供例如治疗有需要的患者的精神分裂症、双相障碍和/或认知损害病症的方法，其包括施用例如雷帕替奈和非典型抗精神病药。

  公开号：

  CN108601814A

文献信息

• SECONDARY STRUCTURE STABILIZED NMDA RECEPTOR MODULATORS AND USES THEREOF
  申请人：Northwestern University

  公开号：US20160115197A1

  公开（公告）日：2016-04-28

  Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain.

  本发明揭示了在调节NMDA受体活性方面具有增强效力的化合物。此类化合物可用于治疗学习、认知活动和镇痛等疾病和障碍，特别是在缓解和/或减轻神经病理性疼痛方面。
• NMDA Receptors Modulators and Uses Thereof
  申请人：Moskal Joseph

  公开号：US20130035292A1

  公开（公告）日：2013-02-07

  Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

  本发明涉及具有增强效力的化合物，其可调节NMDA受体活性。这样的化合物可用于治疗疾病和疾病，如学习、认知活动和镇痛，特别是减轻和/或减少神经病理性疼痛。本发明还公开了口服制剂和其他药学上可接受的化合物给药形式，包括静脉给药制剂。
• NMDA receptors modulators and uses thereof
  申请人：Moskal Joseph

  公开号：US08673843B2

  公开（公告）日：2014-03-18

  Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

  本发明涉及具有增强的NMDA受体活性调节效能的化合物。这样的化合物可用于治疗疾病和疾病，如学习、认知活动和镇痛，特别是在缓解和/或减轻神经病性疼痛方面。还揭示了口服制剂和其他药学上可接受的化合物递送形式，包括静脉制剂。
• NMDA RECEPTOR MODULATORS AND USES THEREOF
  申请人：Northwestern University

  公开号：US20150051262A1

  公开（公告）日：2015-02-19

  Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

  本发明涉及具有增强的NMDA受体活性调节作用的化合物。这样的化合物被考虑用于治疗疾病和障碍，如学习、认知活动和镇痛，特别是在缓解和/或减轻神经病理性疼痛方面。本发明还公开了口服制剂和其他药学可接受的化合物给药形式，包括静脉注射制剂。
• NMDA Receptor Modulators and Uses Thereof
  申请人：Northwestern University

  公开号：US20150315237A1

  公开（公告）日：2015-11-05

  Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

  本发明涉及具有增强的NMDA受体活性调节功效的化合物。这些化合物可用于治疗疾病和障碍，如学习、认知活动和镇痛，特别是在缓解和/或减轻神经病理性疼痛方面。本发明还揭示了口服制剂和其他药学上可接受的化合物递送形式，包括静脉注射制剂。